Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity

Diane N Singhroy; Mark A Wainberg; Thibault Mesplède

doi:10.1128/AAC.05181-14

Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity

Diane N Singhroy
, Mark A Wainberg
, Thibault Mesplède

Lady Davis Institute for Medical Research (LDI)

Research output: Contribution to journal › Article › Academic › peer-review

20 Citations (Scopus)

Abstract

We investigated the effect of combining the dolutegravir-specific R263K integrase resistance substitution with either M184I or M184V, two reverse transcriptase drug resistance substitutions that are frequently detected in individuals failing therapeutic regimens containing either lamivudine or emtricitabine. The presence of R263K and M184I/V in a single virus resulted in substantial further decreases in the viral replicative capacity compared to that in the presence of single substitutions alone.

Original language	English
Pages (from-to)	2882-5
Number of pages	4
Journal	Antimicrobial Agents and Chemotherapy
Volume	59
Issue number	5
DOIs	https://doi.org/10.1128/AAC.05181-14
Publication status	Published - May 2015
Externally published	Yes

Bibliographical note

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1128/AAC.05181-14

Cite this

@article{1e6b7b47b6b947599c92af0a2d937f58,

title = "Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity",

abstract = "We investigated the effect of combining the dolutegravir-specific R263K integrase resistance substitution with either M184I or M184V, two reverse transcriptase drug resistance substitutions that are frequently detected in individuals failing therapeutic regimens containing either lamivudine or emtricitabine. The presence of R263K and M184I/V in a single virus resulted in substantial further decreases in the viral replicative capacity compared to that in the presence of single substitutions alone.",

author = "Singhroy, \{Diane N\} and Wainberg, \{Mark A\} and Thibault Mespl{\`e}de",

year = "2015",

month = may,

doi = "10.1128/AAC.05181-14",

language = "English",

volume = "59",

pages = "2882--5",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "5",

}

TY - JOUR

T1 - Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity

AU - Singhroy, Diane N

AU - Wainberg, Mark A

AU - Mesplède, Thibault

PY - 2015/5

Y1 - 2015/5

N2 - We investigated the effect of combining the dolutegravir-specific R263K integrase resistance substitution with either M184I or M184V, two reverse transcriptase drug resistance substitutions that are frequently detected in individuals failing therapeutic regimens containing either lamivudine or emtricitabine. The presence of R263K and M184I/V in a single virus resulted in substantial further decreases in the viral replicative capacity compared to that in the presence of single substitutions alone.

AB - We investigated the effect of combining the dolutegravir-specific R263K integrase resistance substitution with either M184I or M184V, two reverse transcriptase drug resistance substitutions that are frequently detected in individuals failing therapeutic regimens containing either lamivudine or emtricitabine. The presence of R263K and M184I/V in a single virus resulted in substantial further decreases in the viral replicative capacity compared to that in the presence of single substitutions alone.

U2 - 10.1128/AAC.05181-14

DO - 10.1128/AAC.05181-14

M3 - Article

C2 - 25666155

SN - 0066-4804

VL - 59

SP - 2882

EP - 2885

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 5

ER -

Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity

Abstract

Bibliographical note

UN SDGs

Access to Document

Fingerprint

Cite this